Your browser doesn't support javascript.
loading
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb, J; Balogoun, R; Le Malicot, K; Tabernero, J; Mini, E; Folprecht, G; Van Laethem, J-L; Emile, J-F; Mulot, C; Fratté, S; Levaché, C-B; Saban-Roche, L; Thaler, J; Petersen, L N; Bridgewater, J; Perkins, G; Lepage, C; Van Cutsem, E; Zaanan, A; Laurent-Puig, P.
Afiliação
  • Taieb J; Paris Descartes University, Paris Sorbonne cité, Department of Digestive Oncology, HEGP, Paris, France.
  • Balogoun R; Biology, Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, INSERM UMR-S1147, Paris, France.
  • Le Malicot K; Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France.
  • Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Universitat Autònoma de Barcelona, Spanish Gastrointestinal Tumours TTD Group, Barcelona, Spain.
  • Mini E; Department of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, Florence, Italy.
  • Folprecht G; Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Van Laethem JL; Department of Gastroenterology, Hôpital Universitaire Erasme, Brussels, Belgium.
  • Emile JF; Pathology Department, Ambroise Paré Hospital, Boulogne, France.
  • Mulot C; Université Paris Descartes, Sorbonne Paris Cité, CRB EPIGENETEC, INSERM UMR-S1147, Paris, France.
  • Fratté S; Department of Gastroenterology, Centre Hospitalier de Belfort-Montbeliard, Belfort, France.
  • Levaché CB; Department of Radiotherapy and Medical Oncology, Polyclinique Francheville, Périgueux, France.
  • Saban-Roche L; Department of medical Oncology, Institut de Cancerologie de la Loire, Saint-Priest-En-Jarez, France.
  • Thaler J; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
  • Petersen LN; Department of Oncology, Rigshospitalet, København, Denmark.
  • Bridgewater J; UCL Cancer Institute, University College London, London, UK.
  • Perkins G; Biology, Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, INSERM UMR-S1147, Paris, France.
  • Lepage C; Université Sorbonne Paris Cité, INSERM UMR-S1147, CNRS SNC 5014, Centre Universitaire des Saints-Pères, Equipe labélisée LIGUE Contre le Cancer, Paris, France.
  • Van Cutsem E; Hepato-Gastroenterology Department, Dijon University Hospital and INSERM U 866, Dijon, France.
  • Zaanan A; Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
  • Laurent-Puig P; Biology, Université Paris Descartes, Sorbonne Paris Cité; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, INSERM UMR-S1147, Paris, France.
Ann Oncol ; 28(4): 824-830, 2017 04 01.
Article em En | MEDLINE | ID: mdl-28031175
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Neoplasias do Colo / Cetuximab Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Neoplasias do Colo / Cetuximab Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article